There is just one small problem: The company’s market cap is $73.6 million shares.

Oculus has developed, manufactures, and sells a family of products intended to prevent and treat infections in chronic and acute wounds.  Its platform Microcyn is a proprietary oxychlorine small molecule formulation that is designed to treat a wide range of organisms that cause disease, including viruses, fungi, spores and antibiotic resistant strains of bacteria, in wounds.  Microcyn is NOT approved by the FDA.  Its device product is cleared for sale in the United States as a medical device for wound cleaning, or debridement, lubricating, moistening and dressing; is a device under CE Mark in Europe with anti-infective claims; and is approved as a drug in India and as an antiseptic in Mexico.

It recently began enrolling patients in Phase II Microcyn studies in mildly infected diabetic foot ulcers and is currently pursuing strategic partnerships to assess potential applications for Microcyn in several other markets.

Shares rose some 6% today to $5.55, and shares are only down 0.8% in after-hours trading. 

Jon C. Ogg
February 13, 2008